Ipsos: Growth acceleration
Q3 revenue: 588 million euros
Organic growth: 4.3%
Paris, October 26th, 2023 – Ipsos, one of the world's leading market research companies, confirms the acceleration of its activity in Q3, in which it recorded 4.3% organic growth (after -2.8% in Q1 and 0.5% in Q2). This illustrates the good momentum of the Group’s activity, despite headwinds on major Tech clients and a weak economic recovery in China.
Revenue for the first nine months of the year stands at 1,675.1 million euros, with 0.8% organic growth. Total growth stands at -2.8% due to significant unfavorable exchange rate effects (-3.5%) and slight perimeter effects.
PERFORMANCE BY QUARTER
|2023 vs. 2022|
|In millions of euros||2023|
PERFORMANCE BY REGION
|In millions of euros||2023 9 months revenue||Contribution||Q3 Organic growth||Organic|
growth over 9 months
All regions recorded organic growth in Q3.
The activity in EMEA shows good momentum, with nearly 7% organic growth over the quarter and 1.4% year to date, mainly driven by Continental Europe. This quarter is the first one no longer affected by negative base effects related to the end of Covid contracts.
Business in the Americas is growing organically by more than 2% in Q3, reflecting contrasting situations in Latin America (8% organic growth) and North America (slightly under 2%). In the United States, declining demand from major Tech clients continued to weigh on our activity during the summer. However, ongoing discussions with these major clients, both on traditional market research activities and on new opportunities related to generative AI, are encouraging.
Finally, Asia-Pacific is recording around 3% organic growth this quarter. In China, the weakness of the economic rebound is weighing on our activity, but India and Southeast Asia have kept their momentum, with double-digit growth.
PERFORMANCE BY AUDIENCE
|In millions of|
9 months revenue
|Contribution||Q3 Organic growth||Organic growth |
over 9 months
|Customers and employees2||372.1||22%||-3.3%||-0.9%|
|Doctors and patients4||262.6||16%||5.7%||0%|
Breakdown of Service Lines by audience segment:
1- Brand Health Tracking, Creative Excellence, Innovation, Ipsos UU, Ipsos MMA, Market Strategy &
Understanding, Observer (excl. public sector), Social Intelligence Analytics, Strategy3
2- Automotive & Mobility Development, Audience Measurement, Customer Experience, Channel
Performance (Mystery Shopping and Shopper), Media development, ERM, Capabilities
3- Public Affairs, Corporate Reputation
4- Pharma (quantitative and qualitative)
Our Service Lines focusing on the understanding of consumers, mainly in the consumer goods sector, are recording 8.3% organic growth in Q3. Our activities in the fields of brand perception measurement and analysis, optimizing marketing and market positioning expenses, innovation, as well as qualitative surveys all deliver sustained growth.
Our work on clients and employees is down by 3.3% in Q3, affected by major Tech clients.
Our activity on citizens is growing by 2.8% in Q3 and no longer impacted by the end of Covid contracts.
Finally, our activity with doctors and patients is improving from quarter to quarter, with nearly 6% organic growth in Q3. This reflects the end of post-Covid restructuring in this sector and a normalization of new drugs approvals.
The clear acceleration we are seeing in Q3 will continue and intensify over the rest of the year. This momentum will be supported in Q4 by more favorable base effects.
We confirm our organic growth target of between 3 and 4%, alongside an operating margin of around 13% – demonstrating the resilience of our model, our ability to control costs and improve our gross margin.
Ipsos is one of the largest market research and polling companies globally, operating
in 90 markets and employing nearly 20,000 people.
Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 business solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.
“Game Changers” – our tagline – summarizes our ambition to help our 5,000 clients navigate with confidence our rapidly changing world.
Founded in France in 1975, Ipsos has been listed on the Euronext Paris since July 1, 1999. The company is part of the SBF 120 and Mid-60 indices and is eligible for the Deferred Settlement Service (SRD).
ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP www.ipsos.com
35 rue du Val de Marne
75 628 Paris, Cedex 13 France
Tél. + 33 1 41 98 90 00
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®29.11.2023 10:00:00 CET | Press release
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab). The study, which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult subjects, met its primary endpoints. “These results demonstrate the strength of our platform approach to biosimilars development and manufacture, combining a well-designed and executed clinical study with the design of a high-quality manufacturing process and strong analytical capabilities,” said Joseph McClellan, Chief Scientific Officer. “As we progress more biosimilar candidates through clinical development and approval, w
The notes bought back by Municipality Finance will be removed from trading at Nasdaq Helsinki29.11.2023 10:00:00 CET | Press release
Municipality Finance Plc Stock exchange release 29 November 2023 at 11:00 am (EET) The notes bought back by Municipality Finance will be removed from trading at Nasdaq Helsinki On 27 November 2023 Municipality Finance Plc announced that it has bought back its EUR 10 million notes (ISIN XS2485560481) in whole. Nasdaq Helsinki has today approved MuniFin’s application to remove the notes from trading. MUNICIPALITY FINANCE PLC Further information: Joakim Holmström Executive Vice President, Capital Markets and Sustainability tel. +358 50 444 3638 MuniFin (Municipality Finance Plc) is one of Finland’s largest credit institutions. The owners of the company include Finnish municipalities, the public sector pension fund Keva and the Republic of Finland. MuniFin Group also includes the subsidiary company, Financial Advisory Services Inspira Ltd. The Group’s balance sheet totals approximately EUR 48 billion. MuniFin builds a better and more sustainable future with its customers. Our customers inc
Investeringsforeningen PortfolioManager - anmodning om suspension i afdeling29.11.2023 09:44:09 CET | pressemeddelelse
Pga. tekniske udfordringer har Investeringsforeningen PortfolioManager anmodet om suspension med handel af følgende afdelinger/andelsklasser: Afdelinger/andelsklasser i Investeringsforeningen PortfolioManagerFondskodeShortnameAI Alpha Lab Globale Aktier, kl nDK0062612644PMIAAN Suspensionen vil blive ophævet, når de tekniske udfordringer er løst, og det igen er muligt at stille priser. Eventuel henvendelse vedrørende denne meddelelse kan rettes til undertegnede på tlf. 38 42 21 42. Med venlig hilsen Nina Trolle Boldt, adm. direktør Fundmarket A/S
Buy-backs of shares in CoinShares International Limited29.11.2023 09:00:00 CET | Press release
29 November 2023 | SAINT HELIER, Jersey - As announced on 07 November 2023, the Board of Directors of CoinShares International Limited ("CoinShares" or the "Company") (Nasdaq Stockholm Market: CS; US OTCQX: CNSRF), Europe's leading alternative asset manager specialising in digital assets, resolved to extend a share buy-back program and repurchase shares on Nasdaq Stockholm Market during the period 07 November 2023, up to and including 30 May 2024 for total maximum amount of SEK 30 million in accordance with the authorisation from the Annual General Meeting on 31 May 2023. The Board of Directors’ resolution to implement the share buy-back program was made after the Board's review of the Company's capital structure and was implemented for the purposes of reducing the capital of the Company. The share buy-back program is carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulatio
Deutsche Digital Assets Wins Pension Fund as Anchor Investor for DDA Crypto Select 10 ETP (SLCT)29.11.2023 09:00:00 CET | Press release
Institutional anchor investor for DDA Crypto Select 10 ETP (ISIN: DE000A3G3ZD0; WKN: A3G3ZD, Ticker: SLCT) The DDA Crypto Select 10 ETP reflects the MarketVector™ Digital Assets Max 10 VWAP Close Index (“MVDAMV”)With the ETP, investors are in a position to affordably gain exposure to a basket collection of (up to) the 10 most important crypto assetsThe ETP is 100% collateralized by coins held in an institutional custody solution FRANKFURT, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Deutsche Digital Assets GmbH has gained a renowned institutional anchor investor for the DDA Crypto Select 10 ETP (ISIN: DE000A3G3ZD0 | WKN: A3G3ZD), which was launched in June 2023. DDA prevailed against the competition in a selection process and was commissioned to design a crypto ETP that meets high quality standards and strict requirements of an institutional investor. After several months of preparation, this investment product can now be administered by a leading capital management company acting on be